Stem cell research conducted with pig cells may perhaps be an improved way to settle on the safety of future stem cell therapies than over using mice in stem cell research.
Rodent studies are likely inadequate for testing many human therapies-including pharmaceuticals-since 50 percent of all chemicals test positive as carcinogens in rodents regardless of their source or identity, according to Thomas Hartung, a professor in the Bloomsburg College of Public Health at Johns Hopkins University.
UGA faculty Steve Stice and Franklin West introduced 13 pigs that have shown promise in unlocking the path to new therapies. The pigs recently produced another positive finding: These adult-cell-sourced stem cells don't form tumors in pigs.
"However, tests in mice often resulted in tumor formation that frequently led to death," he said.
The formation of tumors has raised concerns about the safety of induced pluripotent stem cells, or iPSCs, and cells derived from these stem cells. Until now, all iPSC safety studies have been performed in rodent models.
"Being able to safely use iPSCs without the potential of causing tumors is essential for this promising stem cell therapy to become a viable treatment option," said Stice, a Georgia Research Alliance Eminent Scholar in the College of Agricultural and Environmental Sciences.
"We now have graduate students working on making neural cells from the human and pig stem cells to help further the studies," he said.
"The human stem cells were effective in a rodent model for stroke, but rodent studies are not rigorous enough to start human clinical trials," he added.
Additionally, Stice and West have now bred the pigs produced from iPSCs and have proven the stem cells did pass to the offspring.
This finding opens the door for better animal-sourced tissue for human regenerative medicine such as islet cells that produce insulin for diabetic patients.
Their research results were published in the October issue of Stem Cells.